Cefazolin Pharmacokinetics: Elimination Clearance in Neonates

NCT ID: NCT01295606

Last Updated: 2011-12-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-02-28
• Study Completion Date: 2011-12-31

Brief Summary

To document cefazolin disposition (concentration/time profile, protein binding, metabolism, renal elimination characteristics) and its covariates in neonates following intravenous administration of the drug at induction of anesthesia, prior to an invasive procedure

To evaluate if optimalisation of cefazolin dose regimen during neonatal life is needed

Detailed Description

Prospective, single-center, open label study on the pharmacokinetics of iv cefazolin administration in neonates admitted in the neonatal intensive care unit, University Hospitals Leuven, Belgium.

Patients will be included after signed informed consent of the parents.

Our aim is to include 40 neonates. Cefazolin has been selected for this study as it is routinely administered in neonates undergoing invasive procedures in our unit. At this stage, we only have the intention to document pharmacokinetics and covariates based on the current clinical practice and therefore will not interfere with either clinical indication, or with dosing as prescribed by the attending physician.

Drug administration and collection of samples will be obtained to the current clinical and nursing standard procedures.

Routine clinical care for scheduled invasive procedures in neonates in our unit is intravenous administration of cefazolin as follows:

• 50 mg/kg, 3 times a day
• an extra dose of 50mg/kg is given after 3 hours for operations longer than 3 h
• each time one dose/day is excluded for neonates with body weight <2000 g and postnatal age (PNA) <7 days,
• for invasive operations (e.g. open-heart surgery, laparotomy) the prophylactic administration of cefazolin may be continued for 3-5 days following the completion of surgery.

The antibiotic agent should be administered 30 minutes to 1 hour prior to the start of surgery so that adequate antibiotic levels. Cefazolin is administered to the neonate, through a peripherally inserted venous catheter, during 30 minutes.

Blood will be collected in heparinised tubes through an indwelling arterial line, or deep venous access, always when other routine blood samples are collected for clinical purposes (pO2, pCO2, pH).

Urine samples will be collected through a bladder catheter in patients in whom a bladder catheter is available for clinical indications.

Pharmacokinetic analysis A population pharmacokinetics approach will be used, hereby comparing the data on PK already reported in adults or older children and the newly collected data during neonatal life.

Conditions

Prophylaxis

Keywords

cefazolin; prophylaxis; pharmacokinetics; newborn

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Cefazolin, antibiotic prophylaxis

All included patients will received iv cefazolin

Group Type: NO_INTERVENTION

Cefazolin

Intervention Type: DRUG

iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment

Interventions

Cefazolin

iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment

Intervention Type: DRUG

Other Intervention Names

Kefzol

Eligibility Criteria

Inclusion Criteria

• signed parental informed written consent
• neonates to whom cefazolin is administered by intravenous route for clinical indications (invasive procedure)

Exclusion Criteria

• known cefazolin intolerance

• Minimum Eligible Age: 1 Day
• Maximum Eligible Age: 28 Days
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Karel Allegaert, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Universitaire Ziekenhuizen KU Leuven

References

Elkayal O, Allegaert K, Spriet I, Smits A, Seghaye MC, Charlier C, Dreesen E. Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates. J Antimicrob Chemother. 2021 Nov 12;76(12):3229-3236. doi: 10.1093/jac/dkab329.

Reference Type: DERIVED

PMID: 34499720 (View on PubMed)

Other Identifiers

2010-024319-15

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

S52907

Identifier Type: -

Identifier Source: org_study_id